Do GLP-1 drugs lower cancer risk? A 64,000-patient study

TL;DR

A 2025 real-world study of more than 64,000 matched patients found semaglutide, tirzepatide, and bariatric surgery were each linked to lower rates of obesity-associated cancer. But when researchers removed cancers found in the first 6 months, the semaglutide benefit disappeared, a sign the drug signal may reflect timing and detection rather than true prevention.

If you take a GLP-1 medication for weight, you have probably seen the headline that these drugs might lower your cancer risk. A large 2025 study tested that idea directly, comparing semaglutide, tirzepatide, and weight-loss surgery in one real-world dataset. The honest answer is more careful than the headlines, and one buried result changes how you should read all of it.

What the study actually measured

Researchers used TriNetX, a large network of United States health records, to build matched groups of adults who had both type 2 diabetes and overweight or obesity. Each treated group was compared against people taking a DPP-4 inhibitor, a common older diabetes pill that does little to body weight. Matching people on age, sex, BMI and other factors is how observational studies try to compare like with like. The results were published in Diabetes, Obesity and Metabolism in 2025.

The outcome was obesity-associated cancer, a defined group of cancers that occur more often in people carrying excess weight, including colorectal, liver, pancreatic, breast, uterine and kidney cancer. The question was direct: over the following years, did people on these treatments develop fewer of these cancers than people on the DPP-4 pill?

What it found

All three interventions were linked to a lower rate of obesity-associated cancer. Here is the headline comparison, shown as the drop in risk versus the DPP-4 inhibitor group.

Intervention	Obesity-cancer risk vs DPP-4 pill	Statistically significant?
Semaglutide (Ozempic, Wegovy)	12% lower (HR 0.88)	Yes
Tirzepatide (Mounjaro, Zepbound)	16% lower (HR 0.84)	No
Bariatric surgery	15% lower (HR 0.85)	Yes

Semaglutide had the largest matched group, 64,178 pairs, followed for a mean of about two and a half years. Its 12% lower risk (hazard ratio 0.88, 95% confidence interval 0.82 to 0.95) was statistically solid. Looking at single cancers, semaglutide was linked to a 20% lower rate of colorectal cancer, 25% lower liver cancer, and 24% lower pancreatic cancer.

Tirzepatide looked slightly better on paper, at 16% lower, but its confidence interval ran from 0.69 to 1.01. Because that range crosses 1.0, the result was not statistically significant, and its group was smaller with only about a year of follow-up. In plain terms, tirzepatide's number is promising but unproven here. Bariatric surgery sat at 15% lower and, notably, was followed the longest, almost five years on average.

The single-cancer results are worth reading with the same caution. Tirzepatide's only statistically significant individual finding was a lower rate of ovarian cancer, but that rested on very few cases, so it should not carry much weight on its own. Surgery cut liver and uterine cancer rates, yet the same analysis flagged higher rates of two rarer cancers, gastric and oesophageal, each based on a tiny handful of events. When a result rides on a few cases, the confidence intervals are wide and the number can swing hard, so these individual signals are best treated as leads for future research, not conclusions.

The result that changes the story

Here is the part the headlines skipped. When the researchers repeated the analysis but excluded any cancer diagnosed within the first 6 months of starting treatment, the semaglutide benefit vanished. The risk went from 12% lower to no difference at all (hazard ratio 1.00, 95% confidence interval 0.92 to 1.09). Bariatric surgery, by contrast, stayed protective.

Why would dropping early cancers erase the drug's benefit? Because a cancer found weeks after starting a drug was almost certainly already growing before the first dose. A medication cannot prevent a tumour that already exists. When those early, pre-existing cancers are counted, they can make a drug look protective simply because of who gets diagnosed and when. Researchers call this reverse causation, and the 6-month exclusion is the standard way to check for it. Semaglutide did not hold up to that test. Surgery did.

Lower incidence is not the same as prevention

This is the honest center of the whole topic. An observational study can show that two groups had different cancer rates, but it cannot prove the drug caused the difference. Several things blur the picture at once:

• People prescribed a newer, expensive drug often differ from people on an older pill in ways records do not capture, such as income, diet and how often they see a doctor.
• Follow-up was short for the drugs, especially tirzepatide, and most cancers take years to develop, so a one-to-two-year window may be too brief to judge true cancer risk.
• The data came only from the United States, and the analysis tested many cancers at once, which raises the chance that some individual findings are down to luck.
• The doses people took and how long they actually stayed on treatment were unknown.

None of this means GLP-1 medications raise cancer risk. This study found no increase in obesity-associated cancer, which is itself reassuring given years of questions about the drugs. It simply means the "Ozempic prevents cancer" story is not settled, and the strongest, most durable signal in this dataset came from sustained weight loss through surgery, not from the drugs themselves.

What this means if you are on a GLP-1

The practical takeaway is steadier than any single hazard ratio. Excess weight and the low-grade inflammation that travels with it are among the clearest drivers of these cancers, and GLP-1 medications produce real, sustained weight loss for most people who stay on them. Protecting that result is where your attention pays off. That means keeping the weight you lose as fat, not muscle, and not letting nutrition slide while your appetite is low.

Rapid weight loss on a GLP-1 can strip lean muscle and open up nutrient gaps, which is why protein intake and micronutrient status matter more, not less, on these drugs. This is the space GLP-1 Shield was built for: supporting the nutrient side of weight loss so the metabolic health you are working toward is not quietly undermined by deficiency. No supplement prevents cancer, and anyone claiming one does is overselling. The point is simpler. Hold onto muscle, keep your vitamins and minerals in range, and protect the weight loss that the evidence actually connects to lower risk.

For the specific cancers this study touched, the deeper picture lives in our related coverage: the colorectal cancer findings, the breast cancer incidence data, and the long-running thyroid cancer question. To protect the weight loss itself, see what we know about muscle loss and protein intake and which supplements to consider on a GLP-1. This article is general information, not medical advice, and your own cancer risk depends on many personal factors, so discuss your situation with your clinician.

Key takeaways

• In 64,178 matched pairs, semaglutide was linked to 12% lower obesity-associated cancer risk over about 2.5 years (HR 0.88).
• Tirzepatide's 16% lower risk was not statistically significant, and its follow-up was only about a year.
• Excluding cancers found in the first 6 months erased the semaglutide benefit (HR 1.00), pointing to detection timing rather than prevention.
• Bariatric surgery's lower risk held up in that same test, making sustained weight loss the most durable signal.

Frequently asked questions

Do GLP-1 drugs prevent cancer?

No. A 2025 real-world study linked semaglutide to a 12% lower rate of obesity-associated cancer, but the benefit disappeared once cancers diagnosed in the first 6 months were excluded (hazard ratio 1.00). That pattern points to detection timing, not prevention. Observational data cannot prove a drug prevents cancer, and follow-up so far is short.

Which lowers cancer risk more, Ozempic or Mounjaro?

In this study, semaglutide (Ozempic, Wegovy) showed a statistically significant 12% lower obesity-cancer rate, while tirzepatide (Mounjaro, Zepbound) showed 16% lower but the result was not statistically significant and had shorter follow-up. Semaglutide has firmer data here, but no head-to-head winner is justified yet.

Does weight-loss surgery lower cancer risk more than GLP-1 drugs?

In this dataset, bariatric surgery's 15% lower obesity-cancer rate was the most durable signal, because it stayed protective after cancers found in the first 6 months were removed and it had nearly five years of follow-up. The drug signals were weaker on that same test. All of it remains observational, not proof of cause.

Do GLP-1 medications cause cancer?

This study found no increase in obesity-associated cancer for semaglutide or tirzepatide versus an older diabetes pill, over the years studied. That is reassuring, though long-standing thyroid-cancer questions are tracked separately and this study was not designed to settle them. Talk to your doctor about your personal risk.